State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications

Veronica Azemawah, Mohammad Reza Movahed, Patrick Centuori, Ryan Penaflor, Pascal L. Riel, Steven Situ, Mehrdad Shadmehr, Mehrnoosh Hashemzadeh

Research output: Contribution to journalReview article

Abstract

Statins are currently the primary treatment for hyperlipidemia, particularly for the treatment of high levels of low-density lipoprotein cholesterol (LDL-C), as many studies have proven benefit in a variety of populations. The benefits of statin treatment for high cholesterol have been proven in many trials. Forefront among different adverse events is statin-induced myopathy, which still eludes complete understanding, and may range anywhere from muscle soreness or fatigue to potentially extremely rare occurrence of rhabdomyolysis. As most adverse events are rare and not life-threatening, in high-risk patients, a high-dose statin should be started initially as data suggests that clinicians rarely up titrate statin therapy after initial prescription leading to under-treatment of many patients requiring high-dose statin therapy. As we will discuss in this paper, musculoskeletal side effects are the main concern and reason for discontinuing statin therapy. The occurrence and true association of other adverse events in patients on statin such as new onset of diabetes, hepatic toxicity, or cognitive impairment are rare, controversial, and not proven. In placebo-controlled studies, abnormal liver function occurs to a similar degree in statin- and placebo-treated patients. This led to FDA removal of the requirement to monitor liver function tests in patients on statin therapy. The combination of statins with other compounds such as ezetimibe or PCSK9 inhibitors has shown some additional benefits in the treatment of hypercholesterolemia. The goal of this manuscript is to conduct a comprehensive review about most commonly used statins and compare data on their history, structures, benefits, adverse effects, and clinical outcomes.

Original languageEnglish (US)
Pages (from-to)625-639
Number of pages15
JournalCardiovascular Drugs and Therapy
Volume33
Issue number5
DOIs
StatePublished - Oct 1 2019

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Clinical Pharmacology
Therapeutics
Placebos
Muscle Fatigue
Rhabdomyolysis
Liver
Liver Function Tests
Myalgia
Muscular Diseases
Hypercholesterolemia
Hyperlipidemias
LDL Cholesterol
Prescriptions
History
Cholesterol

Keywords

  • Atherosclerosis
  • Cholesterol
  • Hypercholesterolemia
  • Hyperlipidemia
  • Low-density lipoprotein-cholesterol (LDL-C)
  • PCSK9 inhibitors
  • Rhabdomyolysis
  • Statins

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications. / Azemawah, Veronica; Movahed, Mohammad Reza; Centuori, Patrick; Penaflor, Ryan; Riel, Pascal L.; Situ, Steven; Shadmehr, Mehrdad; Hashemzadeh, Mehrnoosh.

In: Cardiovascular Drugs and Therapy, Vol. 33, No. 5, 01.10.2019, p. 625-639.

Research output: Contribution to journalReview article

Azemawah, Veronica ; Movahed, Mohammad Reza ; Centuori, Patrick ; Penaflor, Ryan ; Riel, Pascal L. ; Situ, Steven ; Shadmehr, Mehrdad ; Hashemzadeh, Mehrnoosh. / State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications. In: Cardiovascular Drugs and Therapy. 2019 ; Vol. 33, No. 5. pp. 625-639.
@article{3055fc55cf07438e851268a19e47e86d,
title = "State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications",
abstract = "Statins are currently the primary treatment for hyperlipidemia, particularly for the treatment of high levels of low-density lipoprotein cholesterol (LDL-C), as many studies have proven benefit in a variety of populations. The benefits of statin treatment for high cholesterol have been proven in many trials. Forefront among different adverse events is statin-induced myopathy, which still eludes complete understanding, and may range anywhere from muscle soreness or fatigue to potentially extremely rare occurrence of rhabdomyolysis. As most adverse events are rare and not life-threatening, in high-risk patients, a high-dose statin should be started initially as data suggests that clinicians rarely up titrate statin therapy after initial prescription leading to under-treatment of many patients requiring high-dose statin therapy. As we will discuss in this paper, musculoskeletal side effects are the main concern and reason for discontinuing statin therapy. The occurrence and true association of other adverse events in patients on statin such as new onset of diabetes, hepatic toxicity, or cognitive impairment are rare, controversial, and not proven. In placebo-controlled studies, abnormal liver function occurs to a similar degree in statin- and placebo-treated patients. This led to FDA removal of the requirement to monitor liver function tests in patients on statin therapy. The combination of statins with other compounds such as ezetimibe or PCSK9 inhibitors has shown some additional benefits in the treatment of hypercholesterolemia. The goal of this manuscript is to conduct a comprehensive review about most commonly used statins and compare data on their history, structures, benefits, adverse effects, and clinical outcomes.",
keywords = "Atherosclerosis, Cholesterol, Hypercholesterolemia, Hyperlipidemia, Low-density lipoprotein-cholesterol (LDL-C), PCSK9 inhibitors, Rhabdomyolysis, Statins",
author = "Veronica Azemawah and Movahed, {Mohammad Reza} and Patrick Centuori and Ryan Penaflor and Riel, {Pascal L.} and Steven Situ and Mehrdad Shadmehr and Mehrnoosh Hashemzadeh",
year = "2019",
month = "10",
day = "1",
doi = "10.1007/s10557-019-06904-x",
language = "English (US)",
volume = "33",
pages = "625--639",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "5",

}

TY - JOUR

T1 - State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications

AU - Azemawah, Veronica

AU - Movahed, Mohammad Reza

AU - Centuori, Patrick

AU - Penaflor, Ryan

AU - Riel, Pascal L.

AU - Situ, Steven

AU - Shadmehr, Mehrdad

AU - Hashemzadeh, Mehrnoosh

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Statins are currently the primary treatment for hyperlipidemia, particularly for the treatment of high levels of low-density lipoprotein cholesterol (LDL-C), as many studies have proven benefit in a variety of populations. The benefits of statin treatment for high cholesterol have been proven in many trials. Forefront among different adverse events is statin-induced myopathy, which still eludes complete understanding, and may range anywhere from muscle soreness or fatigue to potentially extremely rare occurrence of rhabdomyolysis. As most adverse events are rare and not life-threatening, in high-risk patients, a high-dose statin should be started initially as data suggests that clinicians rarely up titrate statin therapy after initial prescription leading to under-treatment of many patients requiring high-dose statin therapy. As we will discuss in this paper, musculoskeletal side effects are the main concern and reason for discontinuing statin therapy. The occurrence and true association of other adverse events in patients on statin such as new onset of diabetes, hepatic toxicity, or cognitive impairment are rare, controversial, and not proven. In placebo-controlled studies, abnormal liver function occurs to a similar degree in statin- and placebo-treated patients. This led to FDA removal of the requirement to monitor liver function tests in patients on statin therapy. The combination of statins with other compounds such as ezetimibe or PCSK9 inhibitors has shown some additional benefits in the treatment of hypercholesterolemia. The goal of this manuscript is to conduct a comprehensive review about most commonly used statins and compare data on their history, structures, benefits, adverse effects, and clinical outcomes.

AB - Statins are currently the primary treatment for hyperlipidemia, particularly for the treatment of high levels of low-density lipoprotein cholesterol (LDL-C), as many studies have proven benefit in a variety of populations. The benefits of statin treatment for high cholesterol have been proven in many trials. Forefront among different adverse events is statin-induced myopathy, which still eludes complete understanding, and may range anywhere from muscle soreness or fatigue to potentially extremely rare occurrence of rhabdomyolysis. As most adverse events are rare and not life-threatening, in high-risk patients, a high-dose statin should be started initially as data suggests that clinicians rarely up titrate statin therapy after initial prescription leading to under-treatment of many patients requiring high-dose statin therapy. As we will discuss in this paper, musculoskeletal side effects are the main concern and reason for discontinuing statin therapy. The occurrence and true association of other adverse events in patients on statin such as new onset of diabetes, hepatic toxicity, or cognitive impairment are rare, controversial, and not proven. In placebo-controlled studies, abnormal liver function occurs to a similar degree in statin- and placebo-treated patients. This led to FDA removal of the requirement to monitor liver function tests in patients on statin therapy. The combination of statins with other compounds such as ezetimibe or PCSK9 inhibitors has shown some additional benefits in the treatment of hypercholesterolemia. The goal of this manuscript is to conduct a comprehensive review about most commonly used statins and compare data on their history, structures, benefits, adverse effects, and clinical outcomes.

KW - Atherosclerosis

KW - Cholesterol

KW - Hypercholesterolemia

KW - Hyperlipidemia

KW - Low-density lipoprotein-cholesterol (LDL-C)

KW - PCSK9 inhibitors

KW - Rhabdomyolysis

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=85076216069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076216069&partnerID=8YFLogxK

U2 - 10.1007/s10557-019-06904-x

DO - 10.1007/s10557-019-06904-x

M3 - Review article

C2 - 31773344

AN - SCOPUS:85076216069

VL - 33

SP - 625

EP - 639

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 5

ER -